In vitro approaches for studying the inhibition of drug metabolism enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1201/b14003-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.

  2000cited by this paper
• Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole.

  2000cited by this paper
• Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.

  1999cited by this paper
• Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery.

  1999cited by this paper
• Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes

  1999cited by this paper
• Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.

  1999cited by this paper
• Toxicokinetics of 2',3'-didehydro-3'-deoxythymidine, stavudine (D4T).

  1999cited by this paper
• Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions.

  1999cited by this paper
• P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.

  1999cited by this paper
• Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Pharmacokinetics and metabolism in early drug discovery.

  1999cited by this paper
• Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity.

  1999cited by this paper
• Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.

  1999cited by this paper
• The use of heterologously expressed drug metabolizing enzymes--state of the art and prospects for the future.

  1999cited by this paper
• Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.

  1999cited by this paper
• Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein

  1999cited by this paper
• Monospecific antipeptide antibody to cytochrome P-450 2B6.

  1999cited by this paper
• Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.

  1999cited by this paper
• The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.

  1999cited by this paper
• Concise review of the cytochrome P450s and their roles in toxicology.

  1999cited by this paper
• Molecular and physical mechanisms of first-pass extraction.

  1999cited by this paper
• High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.

  1999cited by this paper
• Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

  1999cited by this paper
• Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment.

  1999cited by this paper
• Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.

  1999cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety.

  1998cited by this paper
• In vitro approaches to predicting drug interactions in vivo.

  1998cited by this paper
• Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

  1998cited by this paper
• Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.

  1998cited by this paper
• Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A

  1998cited by this paper
• Metabolism of the Newer Antidepressants

  1998cited by this paper
• Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities.

  1998cited by this paper
• In vitro assessment of human cytochrome P450.

  1998cited by this paper
• Human cytochrome P450s: selectivity and measurement in vivo.

  1998cited by this paper
• Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.

  1998cited by this paper
• In vitro and in vivo drug interactions involving human CYP3A.

  1998cited by this paper
• Further characterization of the expression in liver and catalytic activity of CYP2B6.

  1998cited by this paper
• Xenobiotic-enhanced expression of cytochromes P450 2E1 and 2B in primary cultured rat hepatocytes.

  1998cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998cited by this paper
• Bile acid and xenobiotic transporters in liver.

  1998cited by this paper
• Inhibition and induction of human cytochrome P450 (CYP) enzymes.

  1998cited by this paper
• Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.

  1997cited by this paper
• Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.

  1997cited by this paper
• Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.

  1997cited by this paper
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997cited by this paper
• Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam.

  1997cited by this paper
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

  1997cited by this paper
• Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

  1997cited by this paper
• Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.

  1997cited by this paper
• Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.

  1997cited by this paper
• Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.

  1997cited by this paper
• Characterization of the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes: a role for cytochrome P4502E1 at low substrate concentrations.

  1996cited by this paper
• The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations.

  1996cited by this paper
• Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

  1996cited by this paper
• Nomenclature for human CYP2D6 alleles.

  1996cited by this paper
• Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.

  1996cited by this paper
• Identification of the human P450 enzymes involved in lansoprazole metabolism.

  1996cited by this paper
• Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.

  1996cited by this paper
• Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine.

  1996cited by this paper
• Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors

  1996cited by this paper
• Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans.

  1996cited by this paper
• An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials

  1996cited by this paper
• Models for Assessing Drug Absorption and Metabolism

  1996cited by this paper
• Structural basis of selective cytochrome P450 inhibition.

  1995cited by this paper
• Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.

  1995cited by this paper
• Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes.

  1995cited by this paper
• Structural and catalytic properties of the mammalian flavin-containing monooxygenase.

  1995cited by this paper
• Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

  1995cited by this paper
• CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4.

  1995cited by this paper
• Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram.

  1995cited by this paper
• The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo.

  1994cited by this paper
• Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7 alpha- and coumarin 7-hydroxylations.

  1994cited by this paper
• Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450.

  1994cited by this paper
• Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan.

  1994cited by this paper
• Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid.

  1994cited by this paper
• Use of in vitro human metabolism studies in drug development. An industrial perspective.

  1994cited by this paper
• Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

  1994cited by this paper
• Inhibition of Terfenadine Metabolism

  1994cited by this paper
• Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

  1994cited by this paper
• Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

  1994cited by this paper
• In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic Interaction

  1994cited by this paper
• Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

  1994cited by this paper
• Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

  1993cited by this paper
• Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.

  1993cited by this paper
• Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.

  1993cited by this paper
• Role of flavin-dependent monooxygenases and cytochrome P450 enzymes in the sulfoxidation of S-methyl N,N-diethylthiolcarbamate.

  1993cited by this paper
• A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4-trifluoromethylcoumarin.

  1993cited by this paper
• Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin

  1992cited by this paper
• Dextromethorphan: Enhancing its systemic availability by way of low‐dose quinidine‐mediated inhibition of cytochrome P4502D6

  1992cited by this paper
• Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation.

  1992cited by this paper
• Formation of glutathionyl-spironolactone disulfide by rat liver cytochromes P450 or hog liver flavin-containing monooxygenases: a functional probe of two-electron oxidations of the thiosteroid?

  1991cited by this paper
• Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects.

  1991cited by this paper
• Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.

  1991cited by this paper
• Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.

  1990cited by this paper
• Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole

  1990cited by this paper
• Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype

  1989cited by this paper
• Formation of reactive intermediates and metabolites: effects of macrolide antibiotics on cytochrome P-450.

  1987cited by this paper
• Oxidation of quinidine by human liver cytochrome P-450.

  1986cited by this paper

• In vitro inhibition and induction of human liver cytochrome P450 enzymes by a novel anti-fibrotic drug fluorofenidone

  2020cites this paper
• Assessment of drug–drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase

  2019cites this paper
• Assessment of inhibition of porcine hepatic cytochrome P450 enzymes by 48 commercial drugs.

  2016cites this paper
• Pomalidomide: Evaluation of cytochrome P450 and transporter‐mediated drug–drug interaction potential in vitro and in healthy subjects

  2015cites this paper
• Investigating the chemical space and metabolic bioactivation of natural products and cross-reactivity of chemical inhibitors in CYP450 phenotyping

  2014cites this paper
• Human Placental Lactogen Induces CYP 2 E 1 Expression via PI 3-Kinase Pathway in Female Human Hepatocytes s

  2014cites this paper
• In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters

  2013cites this paper
• Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.

  2013cites this paper
• PREDICTING POTENTIAL CYP450 ENZYME INHIBITION BASED DRUG-DRUG INTERACTION DURING DRUGS PRESCRIPTION USING A COMPUTER AID

  2013cites this paper
• Mechanism-based CYP2D6 inactivation by acridone alkaloids of Indonesian medicinal plant Lunasia amara.

  2012cites this paper
• Complementary products and drug interactions: screening for the potential to cause pharmacokinetic interactions

  2012cites this paper
• Drug-drug interactions and cooperative effects detected in electrochemically driven human cytochrome P450 3A4.

  2012cites this paper
• The roles of different porcine cytochrome P450 enzymes and cytochrome b5A in skatole metabolism.

  2012cites this paper
• A Comprehensive Review of the Carcinogenic and Anticarcinogenic Potential of Capsaicin

  2012cites this paper
• Safety Evaluation of a Proprietary Food-Grade, Dried Fermentate Preparation of Saccharomyces cerevisiae

  2012cites this paper
• Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System

  2012cites this paper
• Casopitant: In Vitro Data and SimCyp Simulation to Predict In Vivo Metabolic Interactions Involving Cytochrome P450 3A4

  2011influential citation
• Chlorzoxazone Metabolism by Porcine Cytochrome P450 Enzymes and the Effect of Cytochrome b5

  2010cites this paper
• Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin

  2010cites this paper
• Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective

  2010cites this paper
• Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters.

  2010cites this paper
• Anticipating and Minimizing Drug Interactions in a Drug Discovery and Development Setting: An Industrial Perspective

  2010cites this paper
• Identification of a novel carbamoyl glucuronide as a metabolism-dependent inhibitor of CYP 2 C 8

  2010cites this paper
• Glucuronidation of Chloramphenicol

  2009cites this paper
• STUDIES ON CYP 2 C 8-MEDIATED DRUG INTERACTIONS

  2008cites this paper
• Inhibition of CYP1A2-mediated drug metabolism in vitro and in humans : With special emphasis on rofecoxib and other NSAIDs

  2008cites this paper
• In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.

  2008cites this paper
• STUDIES ON CYP2C8-MEDIATED DRUG INTERACTIONS

  2008cites this paper
• Inhibition and induction of human cytochrome P450 enzymes: current status

  2008cites this paper
• A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1′,1″-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6

  2007cites this paper
• P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.

  2007cites this paper
• In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography.

  2007cites this paper
• Cytochrome P450 reaction-phenotyping: an industrial perspective

  2007cites this paper
• Risk Assessment for Drug-Drug Interaction Caused by Metabolism-Based Inhibition of CYP3A Using Automated in Vitro Assay Systems and Its Application in the Early Drug Discovery Process

  2007cites this paper
• In vitro metabolism of indiplon and an assessment of its drug interaction potential

  2007cites this paper
• Alkamides from Piper nigrum L. and Their Inhibitory Activity against Human Liver Microsomal Cytochrome P450 2D6 (CYP2D6)

  2006cites this paper
• A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.

  2006cites this paper
• GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

  2006cites this paper
• Malathion detoxification by human hepatic carboxylesterases and its inhibition by isomalathion and other pesticides

  2006cites this paper
• EFFECT OF CYTOCHROMES P450 CHEMICAL INHIBITORS AND MONOCLONAL ANTIBODIES ON HUMAN LIVER MICROSOMAL ESTERASE ACTIVITY

  2006cites this paper
• Cytochrome P450 Enzymes and Drug—Drug Interactions: An Update on the Superfamily

  2006cites this paper
• Cytochrome P450 enzymes— in vitro , in vivo , and in silico studies

  2006cites this paper
• Predicting Inhibitory Drug—Drug Interactions and Evaluating Drug Interaction Reports Using Inhibition Constants

  2005cites this paper
• Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract.

  2005cites this paper
• DIRECT DETERMINATION OF UNBOUND INTRINSIC DRUG CLEARANCE IN THE MICROSOMAL STABILITY ASSAY

  2005cites this paper
• Impact of end-product inhibition on the determination of in vitro metabolic clearance

  2005cites this paper
• Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition.

  2005cites this paper
• Accelerated Communication GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT , METABOLISM-DEPENDENT INHIBITOR OF CYP 2 C 8 : IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

  2005cites this paper
• Human Cytochrome P450: Metabolism of Testosterone by CYP3A4 and Inhibition by Ketoconazole

  2004influential citation
• SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS

  2004cites this paper
• Interaction of dexloxiglumide, a cholecystokinin type‐1 receptor antagonist, with human cytochromes P450

  2004influential citation
• Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

  2004influential citation
• CYTOCHROME P 450 IN VITRO REACTION PHENOTYPING : A RE-EVALUATION OF APPROACHES USED FOR P 450 ISOFORM IDENTIFICATION

  2003cites this paper
• Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.

  2003cites this paper
• Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.

  2003cites this paper
• Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.

  2003cites this paper
• Drug metabolites in safety testing.

  2002cites this paper